We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

20 hedge funds and large institutions have $452K invested in Theriva Biologics in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

11% more funds holding

Funds holding: 18 → 20 (+2)

0% less ownership

Funds ownership: 0.25% → 0.25% (-0%)

21% less capital invested

Capital invested by funds: $573K → $452K (-$120K)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

Holders
20
Holders Change
+2
Holders Change %
+11.11%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
3
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$28.5K
2
VF
Virtu Financial
New York
+$19.3K
3
Jane Street
Jane Street
New York
+$14.9K
4
LNC
Lincoln National Corp
Pennsylvania
+$5.41K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$5.27K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$72K
2
TSS
Two Sigma Securities
New York
-$8.61K
3
Fisher Asset Management
Fisher Asset Management
Washington
-$6.78K
4
BlackRock
BlackRock
New York
-$62
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$49
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$158K -$72K -5,848 -29%
BlackRock
2
BlackRock
New York
$81.7K -$62 -5 -0.1%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$60.7K – – –
Renaissance Technologies
4
Renaissance Technologies
New York
$25K +$2.46K +200 +9%
Citadel Advisors
5
Citadel Advisors
Florida
$24.9K +$28.5K +2,318 New
State Street
6
State Street
Massachusetts
$20.9K – – –
Jane Street
7
Jane Street
New York
$20.5K +$14.9K +1,209 +174%
VF
8
Virtu Financial
New York
$17K +$19.3K +1,565 New
BCM
9
Bridgeway Capital Management
Texas
$12.3K – – –
Northern Trust
10
Northern Trust
Illinois
$11.4K – – –
Charles Schwab
11
Charles Schwab
California
$5.83K – – –
LNC
12
Lincoln National Corp
Pennsylvania
$4.73K +$5.41K +440 New
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
$4.61K +$5.27K +428 New
William Blair & Company
14
William Blair & Company
Illinois
$4.37K +$5K +406 New
Morgan Stanley
15
Morgan Stanley
New York
$444 +$505 +41 New
IA
16
IFP Advisors
Florida
$127 -$37 -3 -20%
Wells Fargo
17
Wells Fargo
California
$99 +$49 +4 +80%
TRCT
18
Tower Research Capital (TRC)
New York
$62 – – –
Osaic Holdings
19
Osaic Holdings
Arizona
$20 -$25 -2 -50%
SPIA
20
Steward Partners Investment Advisory
New York
$6 – – –
Fidelity Investments
21
Fidelity Investments
Massachusetts
$4 -$49 -4 Closed
Bank of America
22
Bank of America
North Carolina
$3 – – –
UBS Group
23
UBS Group
Switzerland
$1 – – –
TSS
24
Two Sigma Securities
New York
– -$8.61K -639 Closed
Fisher Asset Management
25
Fisher Asset Management
Washington
– -$6.78K -503 Closed
1
2

TOVX Hedge Fund Activity: Q4 2023 in Review

20 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q4 2023, worth a combined $452K — down 21% from $573K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new TOVX positions and 4 closed out — a net gain of 2 holders — while 3 added to existing stakes and 4 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $28.5K. The largest seller was Vanguard Group, cutting an estimated $72K.

  • 20 institutional investors held Theriva Biologics (TOVX) as of Q4 2023, up from 18 in Q3 2023.
  • Funds reported $452K of Theriva Biologics stock for Q4 2023, down 21% quarter-over-quarter.
  • 6 funds opened new Theriva Biologics positions in Q4 2023 and 4 closed out, a net change of +2 holders.
  • The largest Theriva Biologics buyer in Q4 2023 was Citadel Advisors, an estimated $28.5K added.
  • The largest Theriva Biologics seller in Q4 2023 was Vanguard Group, an estimated $72K sold.

Based on aggregated 13F filings for Q4 2023.